EU drug pricing

Market Access

Europe’s new HTA reality: The JCA, one year on

Here, we examine the early realities of JCA implementation, exploring whether the system is delivering greater alignment across European markets.

Market Access

5 ways to address pricing and access challenges across the E...

In the feature ‘Successfully navigating the complexity of market access across Europe to improve health equity’, originally published in the European Biopharmaceutical Review, EVERSANA Gene

Sales & Marketing

Is the pharma industry particularly vulnerable to inflation?

The pharma industry is often thought of as one that does not struggle in difficult economic periods – even when times are hard, everyone still values their health.

Views & Analysis

european countries 3d illustration - european continent marked with flags

Resourcing HTA across Europe

With the European Commission looking to formally strengthen health technology assessment (HTA) across Member States, Leela Barham attempts to assess and benchmark the resources currently d

Europe’s new HTA reality: The JCA, one year on

5 ways to address pricing and access challenges across the E...

Is the pharma industry particularly vulnerable to inflation?

Resourcing HTA across Europe

FDA cites 'significant concerns' with ADC lymphoma trial

Discover a new era of healthcare panel engagement: Grounded ...

EU drug pricing

Editor's Picks